Double-Drug attack: new combo aims to tackle tough lung cancer
Disease control
Not yet recruiting
This trial investigates whether combining two drugs—JS212 (given by IV) and JS111 (taken orally)—can safely and effectively shrink tumors in people with advanced non-small cell lung cancer that has a specific EGFR mutation. About 20 participants who have not had prior treatment f…
Phase: NA • Sponsor: Huan Zhou • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC